Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ophthalmic composition

A composition, ophthalmic technology, applied in the directions of drug combination, active ingredients of hydroxyl compounds, drug delivery, etc., can solve the problem of unknown histamine, unpredictable effects of histamine release, and no discussion on the effects of silicone hydrogel lenses, etc. question

Active Publication Date: 2012-07-04
ROHTO PHARM CO LTD
View PDF7 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, the current situation is that for the aforementioned polymers and terpenoids with phosphorylcholine-like groups in their side chains, it is almost unknown what effect they have on the release of histamine, and the effect on histamine release when they are used together can not guess
In addition, the status quo is that there is no research on the influence of silicone hydrogel lenses when they are used together.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmic composition
  • Ophthalmic composition
  • Ophthalmic composition

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0266]

[0267] #1 MPC polymer is the same polymer used in Table 1.

[0268] The prescription of the ophthalmic composition of the above-mentioned formulation example 1 was prepared according to a conventional method, and 15 mL was filled into a 15-mL PET container, and an eye drop and an eye drop for SHCL were prepared respectively.

preparation example 2

[0270]

[0271]

[0272] #1 MPC polymer is the same polymer used in Table 1.

[0273] The ophthalmic composition prescription of the above-mentioned formulation example 2 was prepared according to a conventional method, and 10 mL was filled into a 10 mL capacity PET container to prepare eye drops, contact lens filling solutions, eye drops for SHCL, and contact lens filling solutions for SHCL, respectively. In addition, instead of the above-mentioned container, 500 mL was filled into a 500 mL-capacity PET container, and an eye wash and an eye wash for SHCL were produced, respectively.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are: an ophthalmic composition according to a non-conventional novel preparation, which has histamine release inhibitory action; and an ophthalmic composition for a silicone hydrogel contact lens, which is capable of suppressing adsorption of terpenoid to a silicone hydrogel contact lens. Specifically, the ophthalmic composition is prepared using (A) 0.001-2 w / v% of a polymer that has a phosphorylcholine analogous group in a side chain in combination with (B-1) 0.001-0.02 w / v% of menthol. Meanwhile, the ophthalmic composition for a silicone hydrogel contact lens is prepared using (A) a polymer that has a phosphorylcholine analogous group in a side chain in combination with (B-2) terpenoid.

Description

technical field [0001] The present invention relates to ophthalmic compositions exhibiting an inhibitory effect on histamine release. Moreover, this invention relates to the ophthalmic composition for silicone hydrogel contact lenses which can suppress the adsorption|suction of a terpenoid compound to a silicone hydrogel contact lens. Background technique [0002] In recent years, the increase of allergic patients and the aggravation of allergic symptoms have become a problem. It is known that most of the symptoms of allergic patients are type I allergic symptoms, that is, allergic symptoms caused by the release of chemical transmitters such as histamine from mast cells and basophils through contact with allergens. In order to prevent and improve this type I allergic symptom, it is effective to inhibit the release of histamine itself, and the development of an ophthalmic composition exhibiting a histamine release inhibitory effect has been desired. In particular, if an oph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/78A61K9/08A61K31/045A61K47/10A61K47/32A61P27/02A61P27/04A61P27/14
CPCA61K31/78A61K31/045A61K47/10A61K47/32A61K9/0048A61P23/02A61P27/02A61P27/04A61P27/06A61P27/12A61P27/14A61P29/00A61P31/04A61P37/08A61P43/00
Inventor 松本江利福岛一宏古宫千夏春名健一东田雅美饭塚元气
Owner ROHTO PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com